Dr Peter Feldschreiber co-authors article on the Regulatory Consequences of “Brexit” for the Development of Medicinal Products

News & Judgments
21 July 2017

Brexit is giving rise to great uncertainty regarding the future of life science research and development of new medicines in the UK.  This paper, published in this month’s Journal of Clinical Pharmacology and Therapeutics outlines the potential public health issues and commercial issues to all stakeholders in the Pharmaceutical industry by the disruption to the European life science products regulatory framework.  Dr Peter Feldschreiber and the team at 4 New Square will be happy to advise on these issues.

Related areas



Popular resources

Four Fundamentals of Limitation Periods in Contract and Tort Claims

By Carl Troman, Barrister and Mediator at 4 New Square Four key points…

Discover more

Stay of proceedings before serving a claim form

What should claimants do when limitation is about to expire? Noting…

Discover more

Why are there so many cases against lawyers for contempt of court?

There has been a spate of cases in the past couple of…

Discover more

If you would like to know more or have a question please talk to our clerks

Portfolio Builder

Select the expertise that you would like to download or add to the portfolio

Download    Add to portfolio   
Title Type CV Email

Remove All


Click here to share this shortlist.
(It will expire after 30 days.)